[{"orgOrder":0,"company":"Rosemont","sponsor":"Lucis Pharma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Alimemazine","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Rosemont","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Rosemont \/ Rosemont","highestDevelopmentStatusID":"12","companyTruncated":"Rosemont \/ Rosemont"}]

Find Clinical Drug Pipeline Developments & Deals by Rosemont

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          euroPLX 86 Munich
                          Not Confirmed
                          euroPLX 86 Munich
                          Not Confirmed

                          Details : Through the acquisition, Rosemont will expand its existing portfolio and have access to a pipeline of innovative products including, alimemazine tartrate, an oral solution, used for the management of urticaria and pruritus.

                          Brand Name : Alimemazine Tartrate-Generic

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          June 16, 2023

                          Lead Product(s) : Alimemazine

                          Therapeutic Area : Dermatology

                          Highest Development Status : Approved

                          Recipient : Lucis Pharma

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank